Dr. Reddy's inks settlement agreement with respect to buprenorphine and naloxone sublingual film

24 Jun 2022 Evaluate

Dr. Reddy's Laboratories has entered into a Settlement Agreement with Indivior Inc. and Indivior UK (Indivior UK, and together with Indivior Inc., Indivior) and Aquestive Therapeutics, Inc. (Aquestive). Pursuant to the agreement, the Company will receive payments totalling $72 million by March 31, 2024.

The said agreement resolves all claims between the parties relating to the Company's generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, including Indivior's and Aquestive's patent infringement allegations and the Company's antitrust counterclaims. As part of the settlement, the underlying litigation will be dismissed.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

1258.55 -15.70 (-1.23%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.